AR123793A1 - Compuestos de triazolopiridinilo como inhibidores de quinasas - Google Patents
Compuestos de triazolopiridinilo como inhibidores de quinasasInfo
- Publication number
- AR123793A1 AR123793A1 ARP210102843A ARP210102843A AR123793A1 AR 123793 A1 AR123793 A1 AR 123793A1 AR P210102843 A ARP210102843 A AR P210102843A AR P210102843 A ARP210102843 A AR P210102843A AR 123793 A1 AR123793 A1 AR 123793A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- haloalkyl
- deuteroc1
- deuteroalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos que tienen la fórmula (1) y enantiómeros y diastereómeros, estereoisómeros, sales farmacéuticamente aceptables de los mismos, son útiles como moduladores de quinasas, incluida la modulación RIPK1. Todas las variables son como se definen en el presente documento. Reivindicación 1: Un compuesto que tiene la fórmula (1), o una sal del mismo, en donde R¹ es H, alquilo C₁₋₃, alcoxilo C₁₋₃, haloalquilo C₁₋₃, haloalcoxilo C₁₋₃, deuteroalquilo C₁₋₃, deuteroalcoxilo C₁₋₃, halógeno, o ciclopropilo; R² es H, o halo; R³ es H, halo, o alquilo C₁₋₃ o deuteroalquilo C₁₋₃; R⁴ es H o F; R⁵ᵃ y R⁵ᵇ son cada uno independientemente H, deuterio, alquilo C₁₋₃ o haloalquilo C₁₋₃; alternativamente, R⁵ᵃ y R⁵ᵇ se unen para formar ciclopropilo; R⁶ᵃ y R⁶ᵇ son cada uno independientemente H, deuterio, OH, F, alquilo C₁₋₃, o C(O)-4-fluorofenilo; alternativamente, R⁶ᵃ y R⁶ᵇ son =O, o se unen para formar ciclopropilo o oxetanilo; R⁷ᵃ y R⁷ᵇ son cada uno independientemente H, deuterio, OH, OP(O)(OR)₂, OC(O)NH₂, NH₂, F, alquilo C₁₋₃, alcoxi C₁₋₃, OCD₃, o haloalquilo C₁₋₃; alternativamente, R⁷ᵃ y R⁷ᵇ son =O, o se unen para formar ciclopropilo o oxetanilo; R es H o alquilo C₁₋₃; R⁸ es H, F, Cl, alquilo C₁₋₃, alcoxi C₁₋₃, deuteroalquilo C₁₋₃, o deuteroalcoxi C₁₋₃; R⁹ es H o CH₃; el anillo Z es fenilo, un anillo heteroarilo de 6 miembros que tiene 1 - 2 átomos de nitrógeno, ciclohexilo, ciclopentilo, o ciclobutilo; Y es F, Cl, alquilo C₁₋₃, alcoxi C₁₋₃, CN, haloalquilo C₁₋₃, haloalcoxi C₁₋₃, deuteroalquilo C₁₋₃, deuteroalcoxi C₁₋₃, C(O)OCH₃, o C&
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063093463P | 2020-10-19 | 2020-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123793A1 true AR123793A1 (es) | 2023-01-11 |
Family
ID=78536657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102843A AR123793A1 (es) | 2020-10-19 | 2021-10-14 | Compuestos de triazolopiridinilo como inhibidores de quinasas |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11767322B2 (es) |
| EP (2) | EP4229056B1 (es) |
| JP (1) | JP7730897B2 (es) |
| KR (1) | KR20230092960A (es) |
| CN (1) | CN116802181A (es) |
| AR (1) | AR123793A1 (es) |
| AU (1) | AU2021364302A1 (es) |
| CA (1) | CA3196059A1 (es) |
| CL (1) | CL2023001123A1 (es) |
| CO (1) | CO2023004926A2 (es) |
| DK (1) | DK4229056T3 (es) |
| ES (1) | ES2987662T3 (es) |
| FI (1) | FI4229056T3 (es) |
| HR (1) | HRP20240739T1 (es) |
| HU (1) | HUE067776T2 (es) |
| IL (1) | IL302113A (es) |
| LT (1) | LT4229056T (es) |
| MX (1) | MX2023004492A (es) |
| PE (1) | PE20240219A1 (es) |
| PL (1) | PL4229056T3 (es) |
| PT (1) | PT4229056T (es) |
| RS (1) | RS65620B1 (es) |
| SI (1) | SI4229056T1 (es) |
| SM (1) | SMT202400242T1 (es) |
| TW (1) | TW202233614A (es) |
| WO (1) | WO2022086828A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3580220B1 (en) * | 2017-02-13 | 2021-11-17 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
| JP7600228B2 (ja) | 2019-10-03 | 2024-12-16 | ブリストル－マイヤーズ スクイブ カンパニー | キナーゼ阻害剤としてのインダゾールカルボキサミド |
| AR123793A1 (es) * | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
| WO2025072392A1 (en) | 2023-09-27 | 2025-04-03 | Bristol-Myers Squibb Company | Triazolopyridinyl ether linked compounds as kinase inhibitors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077948A1 (ja) | 2004-02-16 | 2005-08-25 | Daiichi Pharmaceutical Co., Ltd. | 抗真菌作用複素環化合物 |
| US20050288502A1 (en) | 2004-06-25 | 2005-12-29 | Andersen Denise L | Substituted heterocyclic compounds and methods of use |
| ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| EP2277881A4 (en) | 2008-04-18 | 2011-09-07 | Shionogi & Co | HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K |
| WO2010007099A1 (en) | 2008-07-15 | 2010-01-21 | Cellzome Limited | 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
| WO2010007100A1 (en) | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| WO2010057877A1 (en) | 2008-11-18 | 2010-05-27 | Cellzome Limited | 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors |
| US8598163B2 (en) | 2009-02-04 | 2013-12-03 | Vitae Pharmaceuticals, Inc. | Derivatives of [1,3]Oxazin-2-one useful for the treatment of metabolic diseases such as lipid disorders |
| US9783573B2 (en) | 2012-09-18 | 2017-10-10 | Bristol-Myers Squibb Company | IAP antagonists |
| TN2015000542A1 (en) | 2013-06-10 | 2017-04-06 | Bayer Pharma AG | Novel compounds for the treatment of cancer |
| CA2958645A1 (en) | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
| ES2749679T3 (es) | 2014-10-22 | 2020-03-23 | Bristol Myers Squibb Co | Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k |
| ES2807785T3 (es) | 2014-10-22 | 2021-02-24 | Bristol Myers Squibb Co | Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k |
| CN108349970B (zh) | 2015-11-05 | 2021-03-05 | 住友化学株式会社 | 稠合杂环化合物 |
| WO2018017435A1 (en) | 2016-07-22 | 2018-01-25 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof |
| JP7190906B2 (ja) | 2017-01-24 | 2022-12-16 | 住友化学株式会社 | 縮合複素環化合物及びそれを含有する組成物 |
| EP3580220B1 (en) | 2017-02-13 | 2021-11-17 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
| WO2018237370A1 (en) | 2017-06-23 | 2018-12-27 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and method using the same |
| KR102662197B1 (ko) * | 2017-10-30 | 2024-04-29 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서의 아미노이미다조피리다진 |
| JP7307734B2 (ja) | 2018-01-26 | 2023-07-12 | ブリストル－マイヤーズ スクイブ カンパニー | キナーゼ阻害剤としてのアミノピロロトリアジン |
| CA3112519A1 (en) | 2018-09-13 | 2020-03-19 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| AU2019337612A1 (en) | 2018-09-13 | 2021-05-13 | Bristol-Myers Squibb Company | 1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1) |
| WO2020097400A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
| US20220177462A1 (en) | 2019-03-22 | 2022-06-09 | Genfleet Therapeutics (Shanghai) Inc. | Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof |
| JP7600228B2 (ja) | 2019-10-03 | 2024-12-16 | ブリストル－マイヤーズ スクイブ カンパニー | キナーゼ阻害剤としてのインダゾールカルボキサミド |
| CN114230565B (zh) | 2020-09-09 | 2023-10-27 | 成都奥睿药业有限公司 | 5-取代吲哚3-酰胺衍生物及其制备方法和用途 |
| AR123793A1 (es) * | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
-
2021
- 2021-10-14 AR ARP210102843A patent/AR123793A1/es not_active Application Discontinuation
- 2021-10-18 PT PT218057875T patent/PT4229056T/pt unknown
- 2021-10-18 DK DK21805787.5T patent/DK4229056T3/da active
- 2021-10-18 IL IL302113A patent/IL302113A/en unknown
- 2021-10-18 EP EP21805787.5A patent/EP4229056B1/en active Active
- 2021-10-18 CN CN202180070933.6A patent/CN116802181A/zh active Pending
- 2021-10-18 SM SM20240242T patent/SMT202400242T1/it unknown
- 2021-10-18 ES ES21805787T patent/ES2987662T3/es active Active
- 2021-10-18 AU AU2021364302A patent/AU2021364302A1/en not_active Abandoned
- 2021-10-18 SI SI202130138T patent/SI4229056T1/sl unknown
- 2021-10-18 JP JP2023523570A patent/JP7730897B2/ja active Active
- 2021-10-18 CA CA3196059A patent/CA3196059A1/en active Pending
- 2021-10-18 MX MX2023004492A patent/MX2023004492A/es unknown
- 2021-10-18 EP EP24159615.4A patent/EP4364737A3/en active Pending
- 2021-10-18 FI FIEP21805787.5T patent/FI4229056T3/fi active
- 2021-10-18 KR KR1020237016535A patent/KR20230092960A/ko active Pending
- 2021-10-18 WO PCT/US2021/055340 patent/WO2022086828A1/en not_active Ceased
- 2021-10-18 PL PL21805787.5T patent/PL4229056T3/pl unknown
- 2021-10-18 HR HRP20240739TT patent/HRP20240739T1/hr unknown
- 2021-10-18 TW TW110138596A patent/TW202233614A/zh unknown
- 2021-10-18 US US17/503,516 patent/US11767322B2/en active Active
- 2021-10-18 HU HUE21805787A patent/HUE067776T2/hu unknown
- 2021-10-18 PE PE2023001446A patent/PE20240219A1/es unknown
- 2021-10-18 LT LTEPPCT/US2021/055340T patent/LT4229056T/lt unknown
- 2021-10-18 RS RS20240656A patent/RS65620B1/sr unknown
-
2023
- 2023-04-18 CL CL2023001123A patent/CL2023001123A1/es unknown
- 2023-04-19 CO CONC2023/0004926A patent/CO2023004926A2/es unknown
- 2023-07-06 US US18/347,703 patent/US12110290B2/en active Active
-
2024
- 2024-08-28 US US18/817,352 patent/US20240425505A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123793A1 (es) | Compuestos de triazolopiridinilo como inhibidores de quinasas | |
| AR119821A1 (es) | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t | |
| AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| AR114236A1 (es) | Inhibidores de la gcn2 y usos de los mismos | |
| PE20201202A1 (es) | Inhibidores de cinasa dependientes de ciclina | |
| AR093403A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa | |
| AR111419A1 (es) | Compuestos fusionados de indazol piridona como antivirales | |
| MX2019009555A (es) | Aminotriazolopiridinas como inhibidores de cinasa. | |
| AR091022A1 (es) | Inhibidores del nampt | |
| AR130165A1 (es) | Compuestos heterocíclicos, composiciones de los mismos y métodos de tratamiento con ellos | |
| ES2589558T3 (es) | Derivados de pirimidin pirazolilo | |
| AR106798A1 (es) | Inhibidores pirazol de acc y usos de los mismos | |
| AR093504A1 (es) | 4-(orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina como inhibidores de cdk9, un intermediario para su sintesis y metodos de obtencion de ambos compuestos | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| PE20212070A1 (es) | Moduladores de trex1 | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR095530A1 (es) | Moduladores de p2x7 | |
| AR093505A1 (es) | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina | |
| AR096613A1 (es) | Moduladores de la acetil-coa carboxilasa | |
| AR074493A1 (es) | Derivados de quinazolinamida | |
| AR072192A1 (es) | Derivados de tiazolil-piperidina | |
| AR093503A1 (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina | |
| AR101964A1 (es) | Compuestos de imidazopiridazina como moduladores de pi3k | |
| EA201692189A1 (ru) | Соединения фосфина золота (i) в качестве антибактериальных агентов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |